New antibody drug targets Hard-to-Treat metastatic cancers
NCT ID NCT07292168
First seen Jan 05, 2026 · Last updated Jun 16, 2026 · Updated 27 times
Summary
This study tests a new drug called OM-RCA-01 in people with several types of cancer that have spread to other parts of the body and have a specific marker (FGFR1). The drug is an antibody given through a vein every two weeks. The main goals are to find a safe dose and see if it can slow tumor growth. About 58 adults with kidney, lung, prostate, breast, or head and neck cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
A.I. Kryzhanovsky Krasnoyarsk Regional Cancer Center
RECRUITINGKrasnoyarsk, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hadassah Medical
RECRUITINGMoscow, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
I.P. Pavlov First Saint Petersburg State Medical University
RECRUITINGSaint Petersburg, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Republican Clinical Oncology Dispensary
RECRUITINGUfa, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Republican Dispensary of Tatarstan
ACTIVE_NOT_RECRUITINGKazan', Russia
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.